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Hugh Calkins, MDSEE PAGE 635M anagement of patients with atrial ﬁbrilla-tion (AF) can be considered a 3-leggedstool. Physicians caring for AF patients
must consider the issues of rate control, rhythm con-
trol, and stroke prevention and then make speciﬁc
recommendations to their patients that address each
of these issues.
Although each is important, it is well recognized
that the single most important management decision
in AF patients concerns the issue of stroke prevention.
Strokes in patients with AF are often lethal or life
altering. It is for this reason that much attention in
the past decade has focused on creating scoring sys-
tems to assess stroke risk in AF patients, developing
and demonstrating the efﬁcacy of new anticoagulant
drugs, and publishing guidelines that make recom-
mendations regarding which AF patients require
anticoagulation. In the recently updated American
College of Cardiology/American Heart Association and
Heart Rhythm Society (ACC/AHA/HRS) AF guidelines
and the European Society of Cardiology AF guidelines,
the more sensitive CHA2DS2-VASc (congestive heart
failure, hypertension, age 75 years or older, diabetes
mellitus, previous stroke or transient ischemic attack,
vascular disease, age 65 to 74 years, female) risk
stratiﬁcation system has been recommended to assess
stroke risk, replacing the older and less sensitive
CHADS2 score (1,2). Both guidelines advise initiation of*Editorials published in the Journal of the American College of Cardiology
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and Daiichi Sankyo.anticoagulation in patients with a CHA2DS2-VASc score
of $2, and both guidelines advise that patients with a
CHA2DS2-VASc score of 0 not be anticoagulated. The
gray area in both guidelines concerns whether to
anticoagulate patients with a CHA2DS2-VASc score of 1.In this issue of the Journal, Chao et al. (3) report
the stroke risk in AF patients with a single stroke risk
factor irrespective of sex (because the scoring system
considers female sex an independent risk factor). This
was a retrospective study using data obtained from
the National Health Insurance Research Database in
Taiwan, which contains detailed health information
on more than 23 million enrollees in this mandatory
universal health insurance program. From this large
database, 12,935 men and 7,900 women were identi-
ﬁed who met the entry criteria for this study: a
CHA2DS2-VASc score of 1 in men and 2 in women, with
no use of anticoagulant or antiplatelet agents. The
incidence of ischemic stroke was then determined. Of
the 12,935 male AF patients, ischemic stroke occurred
in 14.4% during 5.2  4.3 years of follow-up. The
annual stroke rate was 2.75%, ranging from 1.96% per
year in patients with vascular disease to 3.5% per year
for those 65 to 74 years of age. Of the 9,900 women
with a CHA2DS2-VASc score of 2, ischemic stroke
occurred in 14.9% during 5.2  4.3 years of follow-up.
The overall annual stroke rate was 2.55%, ranging
from 1.91% per year in patients with hypertension to
3.34% per year for those 65 to 74 years of age. The
authors conclude that not all stroke risk factors in the
CHA2DS2-VASc risk score carry equal weight, with
age between 65 and 74 years being the most impor-
tant. They also propose that their data support
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644anticoagulation in patients with a CHA2DS2-VASc
score of 1 in men and 2 in women, especially for those
65 years of age or older.
The results of this study are striking and provide
important new information supporting the practice of
recommending anticoagulation for all AF patients
except those at a very low stroke risk (as identiﬁed by
a CHA2DS2-VASc score of 0 or 1 for women). It is
remarkable that men and women with AF who had a
CHA2DS2-VASc score of 1 (excluding sex) had annual
stroke risks of 2.75% and 2.55%, respectively. This is
markedly higher than the risk of intracranial hemor-
rhage (0.23% to 0.5%) reported in trials of the new
oral anticoagulant drugs: dabigatran (4), rivaroxaban
(5), apixaban (6), and edoxaban (7), referred to as
non–vitamin K antagonist oral anticoagulant agents.
For both groups, age was the most potent single risk
factor, with an annual stroke risk for men and women
between 65 and 74 years of age of 3.5% and 3.34%,
respectively. Considering the safety and efﬁcacy of
antithrombotic therapy, it seems clear that we should
think long and hard before recommending that pa-
tients with a CHA2DS2-VASc score of 1 not receive
anticoagulant therapy.
Another issue concerns the recently published
ACC/AHA/HRS AF management guidelines (2), which
state that for AF patients with a CHA2DS2-VASc score of
1, “no antithrombotic therapy or treatment with an oral
anticoagulant or aspirin may be considered (IIb).” The
guidelines also emphasize that “in patients with AF,
antithrombotic therapy should be individualized based
on shared decision making after discussion of the ab-
solute andRRs of stroke and bleeding, and the patient’s
values and preferences” (Class I) (2). A somewhat
stronger approach is used in the updated European
Society of Cardiology guidelines, which state that in
patients with a CHA2DS2-VASc score of 1, oral antico-
agulant therapy should be considered after assessment
of bleeding risk and patient preferences (Class IIa) (1).
In my mind, it is not time to update the ACC/AHA/
HRS guidelines based on this single study. Althoughthe data are important and inform this discussion,
they are imperfect and not deﬁnitive. After all, this
was a retrospective study in which diagnosis codes
were used to try to tease out a population of patients
with AF who had a CHA2DS2-VASc score of 1, were not
receiving anticoagulant or antiplatelet therapy, and
had experienced a thrombotic stroke. This was not
a prospective, randomized clinical trial comparing
2 management strategies.
At the end of the day, as recommended by the
ACC/AHA/HRS 2014 guidelines for managing patients
with AF, “antithrombotic therapy should be individ-
ualized based on shared decision making after dis-
cussion of the absolute and RRs (relative risks) of
stroke and bleeding, and the patient’s values and
preferences (Class I).” Experienced clinicians recog-
nize that there are many nuances to predicting stroke
risk. For example, hypertension is not a “yes or no”
variable. A patient with a single documented blood
pressure reading over the ideal range is quite
different from a patient with uncontrolled hyperten-
sion. Similarly, a patient who has been in AF for
5 years continuously and has a left atrial size of 5.5 cm
is at far higher stroke risk than a patient with AF and
normal left atrial size who experiences 5 min of AF
per year. There are many other factors that affect
stroke risk, none of which are part of the CHA2DS2-
VASc risk score.
We should commend Chao and colleagues for the
considerable effort put forth to perform and report
this study. There is no doubt in my mind that when
clinicians discuss anticoagulation with their AF pa-
tients with a CHA2DS2-VASc risk score of 1, the bar has
been lowered; more patients will receive anticoagu-
lant therapy, and many strokes will be prevented.
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